FDA to review Corcept's Corlux as Cushing's syndrome treatment

06/30/2011 | Forbes

The FDA accepted a marketing application for Corlux, Corcept Therapeutics' drug candidate for Cushing's syndrome, according to the company. Corlux has been designated an orphan drug, and the FDA is expected to hand down a decision by Feb. 17.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY